OCUGEN, INC. Amortization of Debt Issuance Costs
OCUGEN, INC. (OCGN) reported Amortization of Debt Issuance Costs of $642.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AmortizationOfFinancingCosts · last filed 2026-08-06
- OCUGEN, INC. amortization of debt issuance costs for the quarter ending 2026-06-30 was $265.00K, a 33.75% decline year-over-year.
- OCUGEN, INC. amortization of debt issuance costs for the quarter ending 2026-03-31 was $377.00K, a 20.06% increase year-over-year.
- OCUGEN, INC. amortization of debt issuance costs for the quarter ending 2025-09-30 was $400.00K.
- OCUGEN, INC. amortization of debt issuance costs for the quarter ending 2025-06-30 was $400.00K.
- OCUGEN, INC. amortization of debt issuance costs for fiscal 2025 was $1.36M, a 8412.50% increase from fiscal 2024.
- OCUGEN, INC. amortization of debt issuance costs for fiscal 2024 was $16.00K.
- OCUGEN, INC. amortization of debt issuance costs for fiscal 2014 was $38.00K.
| Period end | Amortization of Debt Issuance Costs 3 month | Amortization of Debt Issuance Costs 3 month as first filed | Amortization of Debt Issuance Costs 6 month | Amortization of Debt Issuance Costs 9 month | Amortization of Debt Issuance Costs 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $265.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $642.00K 10-Q · filed 2026-08-06 | |||
| 2026-03-31 | $377.00K 10-Q · filed 2026-05-08 | ||||
| 2025-12-31 | $1.36M 10-K · filed 2026-03-04 | ||||
| 2025-09-30 | $400.00K 10-Q · filed 2025-11-05 | $800.00K derived: sum of 2 quarters · filed 2025-11-05 | $1.11M derived: sum of 3 quarters · filed 2026-05-08 | ||
| 2025-06-30 | $400.00K 10-Q · filed 2025-08-04 | $0.00 10-Q · filed 2026-08-06 | |||
| 2025-03-31 | $314.00K 10-Q · filed 2026-05-08 | $300.00K 10-Q · filed 2025-05-09 | |||
| 2024-12-31 | $16.00K 10-K · filed 2026-03-04 | ||||
| 2014-12-31 | $77.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-10 | $156.00K derived: sum of 2 quarters · filed 2016-03-10 | $76.00K derived: sum of 3 quarters · filed 2016-03-10 | $38.00K 10-K · filed 2016-03-10 | |
| 2014-09-30 | $79.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-12 | -$1.00K derived: sum of 2 quarters · filed 2015-11-12 | -$39.00K 10-Q · filed 2015-11-12 | ||
| 2014-06-30 | -$80.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-12 | -$118.00K 10-Q · filed 2015-08-12 | |||
| 2014-03-31 | -$38.00K 10-Q · filed 2015-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B |